Source - SMW
AstraZeneca says the US Food and Drug Administration has accepted a complete resubmission of a new drug application for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. 

The FDA has indicated that this is a complete class 2 response.    Interactions with other health authorities in the European Union and Australia are ongoing with decisions expected in the first half of 2017. 

Sodium zirconium cyclosilicate (ZS-9) is an insoluble, non-absorbed compound with a structure that was designed to preferentially capture potassium ions. Sodium zirconium cyclosilicate has been studied in three double-blind, placebo controlled trials and in one ongoing 12-month open label clinical trial in patients with hyperkalaemia which represents over 1,600 patients treated. Sodium zirconium cyclosilicate is an investigational medicine that is not currently approved for any indication in any market.  


At 8:11am: (LON:AZN) AstraZeneca PLC share price was +8.75p at 4983.25p



Related Charts

AstraZeneca (AZN)

-25.50p (-0.63%)
delayed 18:15PM